Structure of human Fyn kinase domain complexed with staurosporine

Biochemical and Biophysical Research Communications

Volumn 346, Issue 3, 2006, Pages 840-844

  Kinoshita, Takayoshi ^a   Matsubara, Mamoru ^b   Ishiguro, Hiroshi ^b   Okita, Kouki ^b   Tada, Toshiji ^a  

^a Osaka Prefecture University   (Japan)

^b 1 5 5 Minatojima Minamimachi   (Japan)

Author keywords

Fyn; Inhibitor; Kinase domain; Non receptor tyrosine kinase; Src family; Staurosporine; X ray crystal structure

Indexed keywords

PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE FYN; STAUROSPORINE;

ANIMAL CELL; ARTICLE; BINDING SITE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; ENZYME ACTIVE SITE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN STRUCTURE; X RAY CRYSTALLOGRAPHY;

ANIMALS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; HUMANS; LYMPHOCYTE SPECIFIC PROTEIN TYROSINE KINASE P56(LCK); MODELS, MOLECULAR; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-FYN; STAUROSPORINE; STRUCTURAL HOMOLOGY, PROTEIN;

EID: 33746863013     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.05.212     Document Type: Article

References (18)

1. Brown M.T., and Cooper J.A. Regulation, substrates and function of Src. Biochem. Biophys. Acta 1287 (1996) 121-149
2. Palacios E.H., and Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23 (2004) 7990-8000
3. Lowenberg M., Tuynman J., Bilderbeek J., Gaber T., Buttgereit F., van Deventer S., Peppelenbosch M., and Hommes D. Rapid immunosuppressive effects of glucocorticoids mediated through Lck and Fyn. Blood 106 (2005) 1703-1710
4. Stachlewits R.F., Hart M.A., Bettencourt B., Kebede T., Schwarts A., Ratnofsky S.E., Calderwood D.J., Waegell W.O., and Hirst G.C. A-770041, a novel and selective small-molecule inhibitor of Lck, prevents heart allograft rejection. J. Pharmacol. Exper. Ther. 315 (2005) 36-41
5. Umemori H., Kadowaki Y., Hirosawa K., Yoshida Y., Hironaka K., Okano H., and Yamamoto T. Stimulation of myelin basic protein gene transcription by Fyn tyrosine kinase for myelination. J. Neurosci. 19 (1999) 1393-1397
6. Chin J., Palop J.J., Puolvali J., Massaro C., Bien-Ly N., Gerstein H., Scearce-Levie K., Masliah E., and Mucke L. Fyn kinase induce synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 9694-9703
7. Hattori K., Uchino S., Isosaka T., Maekawa M., Iyo M., Sato T., Kohsaka S., Yagi T., and Yuasa S. Fyn is required for haloperidol-induced catalepsy in mice. J. Biol. Chem. 281 (2006) 7129-7135
8. Lamers M.B.A.C., Antson A.A., Hubbard R.E., Scott R.K., and Williams D.H. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J. Mol. Biol. 285 (1999) 713-725
9. Morton C.J., Pugh D.J.R., Brown E.L.J., Kahmann J.D., Renzoni D.A.C., and Campbell I.D. Solution structure and peptide binding of the SH3 domain form human Fyn. Structure 4 (1996) 705-714
10. Mulhern T.D., Shaw G.L., Morton C.J., Day A.J., and Campbell I.D. The SH2 domain from the tyrosine kinase Fyn in complex with a phosphotyrosyl peptide reveals insights into domain stability and binding specificity. Structure 5 (1997) 1313-1323
11. Zhu X., Morgenstern K.A., Kim J.L., Rose P.E., Stover D.R., Toledo L.M., and Zhao H. Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. Structure 7 (1999) 651-661
12. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A50 (1994) 157-163
13. Brunger A.T., Adams P.D., Clore G.M., Delano W.L., Gros P., Grosse-Kunstlevve N.S., Jiang J.-S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Simonson L.M., and Warren G.L. Crystallography and NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D54 (1998) 905-921
14. Yamaguchi H., and Hendrickson W.A. Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature 384 (1996) 484-489
15. Hanks S.K., and Hunter T. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9 (1995) 576-596
16. Kuduva S.S., Nangia D.C., and Gautam R. Cubanecarboxylic acids. Crystal engineering considerations and the role of C-H O hydrogen bonds in determining O-H O networks. J. Am. Chem. Soc. 121 (1999) 1936-1944
17. Cherry M., and Williams D.H. Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr. Med. Chem. 11 (2004) 663-673
18. Burchat A., Borhani D.W., Calderwood D.J., Hirst G.C., Li B., and Stachlewitz R.F. Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. Bioorg. Med. Chem. Lett. 16 (2005) 118-122